Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL) Combining 90-Yttrium-Zevalin® and the Redox-Modulating Agent, Motexafin Gadolinium (MGd) (Prot# 106-P115)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/5/031/1/11

Funding

  • Biogen Inc. (NU 02H8 (PCYC-0213) / 106-P115)